Letrozole Sanoswiss

Letrozole, the active ingredient in Letrozole Sanoswiss, is an aromatase inhibitor presented as an oral tablet for oral use. It treats hormone‑receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Sanoswiss as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone‑receptor‑positive early‑stage breast cancer (postmenopausal): reduces risk of recurrence by lowering estrogen production. - Hormone‑receptor‑positive advanced/metastatic breast cancer (postmenopausal): slows disease progression through estrogen suppression. - Adjuvant therapy for postmenopausal breast cancer: supports long‑term disease‑free survival after surgery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hot flashes: transient episodes of increased skin temperature. - Joint and muscle pain: aching discomfort in limbs. - Fatigue: generalized lack of energy. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain. - Elevated cholesterol: modest increase in lipid levels.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated transaminases. - Osteoporotic fractures: increased risk of bone breakage. - Deep vein thrombosis or pulmonary embolism: clot formation in veins. - Cardiovascular events: myocardial infarction or stroke. - Severe allergic reactions: rash, swelling, anaphylaxis. - Hyperglycemia: significant rise in blood glucose levels.

Patients should be monitored for safety considerations before and during therapy. - Monitor bone health: assess bone mineral density periodically. - Check liver function: perform baseline and periodic hepatic enzyme tests. - Assess cardiovascular risk: monitor blood pressure, lipid profile, and signs of thrombosis. - Avoid use in premenopausal women: not indicated for this population. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Letrozole may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly decrease letrozole plasma levels. - Tamoxifen: antagonistic hormonal effects may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may increase INR and bleeding risk. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential alteration of letrozole metabolism. - Statins (e.g., simvastatin): possible changes in lipid‑lowering efficacy. - Hormonal contraceptives: reduced effectiveness due to estrogen suppression. - Thyroid hormone replacement (levothyroxine): may require dose adjustment.